GRF (free acid) (human)
GRF (free acid) (human)
TECHNICAL SPECIFICATIONS
| Item | Specification |
|---|---|
| Product Name | GRF (free acid) (human) |
| CAS NO. | / |
| Appearance | White to off-white lyophilized powder |
| Molecular Formula | C215H357N71O67S |
| Molecular Weight | 5040.74g/mol |
| Purity (RP-HPLC) | ≥98% |
| Solubility | Soluble in water, dilute acetic acid, and DMSO; compatible with physiological buffers. |
| Endotoxin | ≤1.0 EU/mg |
| Biological Activity | Stimulates growth hormone (GH) secretion by activating the GHRHR receptor. |
| Storage Conditions | Store at -20°C to -80°C in a sealed container, protected from moisture and light; avoid repeated freeze-thaw cycles. |
| Stock Location | Stock in USA |
| MOQ | 1g |
1.MECHANISM OF ACTION
Human GRF (free acid) functions as the native, high-affinity endogenous agonist for the Growth Hormone-Releasing Hormone Receptor (GHRHR) on pituitary somatotroph cells. Binding to this Gs-protein coupled receptor activates adenylate cyclase, leading to a significant increase in intracellular cyclic adenosine monophosphate (cAMP).
2.PRODUCT INDICATIONS
Baseline Biological Studies: Establishing the native biological activity and potency of human GRF as a reference standard against which modified analogs (amidated, D-amino acid substituted) are compared.
Receptor-Ligand Interaction Research: Studying the precise binding kinetics, affinity, and conformational changes involved in the natural GRF-GHRHR interaction using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or crystallography.
Enzymatic Degradation Studies: Investigating the kinetics and cleavage sites of proteolytic enzymes like DPP-IV on the native hormone structure.
Antibody & Assay Development: Serving as the native antigen for generating specific antibodies or as the standard in immunoassays (ELISA, RIA) designed to detect endogenous human GRF.
Physiological & Comparative Research: Studying the natural regulation of the GH axis in human cell-based systems or comparing the activity of human GRF to that of other species.
Peptide Chemistry & Modification: Used as the starting material for chemical conjugation, labeling, or specific C-terminal modifications.
3.CLINICAL EFFICACY OF PRODUCT
Physiological Role: It is the natural and potent stimulator of GH secretion. Its efficacy in eliciting GH release is well-established in human physiological studies.
Diagnostic Use: Synthetic GRF (often in stabilized forms) has been used in clinical diagnostic tests (GRF stimulation tests) to assess pituitary function and somatotroph reserve, helping diagnose the cause of growth hormone deficiency.
Therapeutic Development: The short half-life of the native peptide prompted the development of stabilized analogs. Tesamorelin, a DPP-IV-resistant GRF analog, is an FDA-approved drug based on this hormone's action, demonstrating the clinical efficacy achievable by modifying the native sequence.
Research Relevance: This native form remains the critical reference molecule for all biomedical research aimed at understanding GH regulation and for developing improved therapeutic analogs. Its "efficacy" in a clinical context is realized through its synthetic, stabilized derivatives.
4.DELIVERY & SHIPPING
We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods
Main Method: International Air Freight
We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.
May 25, 26
Premium API Oxandrolone Ucinky Manufacturing
Premium API Oxandrolone Ucinky Manufacturing Leading global supplier of high-purity chemical raw materials for pharmaceutical grade Oxandrolone Ucinky, combining precision engineering with industrial scale. 5000 kg Annual Output 120 Countries Served 5 Days Sample Lead Time 99.7 On-Time Delivery Industrial Precision Pure Chemical Synthesis Engineering the future of pharmaceutical intermediates with unmatched stability. Our facility stands as a global leader in the oxandrolone ucinky sector, utilizing CRYOGENIC CRYSTALLIZATION and advanced chromatography to ensure an assay purity exceeding 99.8. We integrate a fully automated closed-loop system that eliminates human error and contamination.
May 22, 26
Clinical Benefits and Applications of Oxandrolone Therapy
Oxandrolone therapy represents a sophisticated intersection of endocrine science and regenerative medicine, primarily utilized to address muscle wasting and metabolic dysfunction. In the global pharmaceutical landscape, this specific approach to androgen therapy is valued for its unique ability to promote protein synthesis while exhibiting a lower androgenic profile compared to traditional steroids, making it a critical tool for patients recovering from severe trauma or chronic illness. From a clinical perspective, understanding the nuances of oxandrolone therapy is essential for optimizing patient outcomes in weight gain and tissue repair.
May 20, 26
Clinical Benefits and Production of Oxandrolone Steroid
The global pharmaceutical landscape has seen a significant rise in the demand for highly specialized anabolic agents, among which the oxandrolone steroid stands out due to its unique chemical profile and therapeutic versatility. As a modified version of dihydrotestosterone, this compound provides a potent means of addressing muscle wasting and metabolic deficits, making it a critical asset in both clinical rehabilitation and advanced physiological research. Understanding the nuances of this synthetic compound is essential for healthcare providers and researchers alike, as it balances efficacy with a relatively lower androgenic profile compared to other steroids.
